middle.news
Race Oncology’s Bisantrene Trial Surpasses Efficacy Goals in Tough AML Cases
2:12pm on Monday 4th of August, 2025 AEST
•
Healthcare
Read Story
Race Oncology’s Bisantrene Trial Surpasses Efficacy Goals in Tough AML Cases
2:12pm on Monday 4th of August, 2025 AEST
Key Points
40% response rate in relapsed/refractory AML patients
Five complete and one partial response achieved
One patient remains disease-free over two years post-treatment
Trial results published in British Journal of Haematology
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RAC
OPEN ARTICLE